Strides Pharma Science Limited (NSE:STAR)
India · Delayed Price · Currency is INR | Market Cap | 73.39B |
| Revenue (ttm) | 46.85B |
| Net Income (ttm) | 3.97B |
| Shares Out | 92.17M |
| EPS (ttm) | 43.12 |
| PE Ratio | 18.47 |
| Forward PE | 12.83 |
| Dividend | 4.00 (0.46%) |
| Ex-Dividend Date | Jul 22, 2025 |
| Volume | 356,502 |
| Average Volume | 332,677 |
| Open | 864.60 |
| Previous Close | 864.60 |
| Day's Range | 791.00 - 864.65 |
| 52-Week Range | 513.05 - 1,025.00 |
| Beta | 0.45 |
| RSI | 34.06 |
| Earnings Date | Jan 30, 2026 |
About Strides Pharma Science
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under th... [Read more]
Financial Performance
Financial StatementsNews
Strides Pharma Science Ltd (BOM:532531) Q2 2026 Earnings Call Highlights: Strong Revenue Growth ...
Strides Pharma Science Ltd (BOM:532531) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Market Positioning
Q2 2026 Strides Pharma Science Ltd Earnings Call Transcript
Q2 2026 Strides Pharma Science Ltd Earnings Call Transcript
Strides Pharma shares hit 52-week high, jumps 3% after Q1 PAT jumps 81% YoY
Shares of Strides Pharma Science Ltd surged over 3% on July 29, hitting a fresh 52-week high of ₹968 on the NSE after the company reported robust Q1FY26 earnings. The stock was last seen trading at ₹9...
Strides Pharma Q1 Results: Revenue rises 6.2% YoY to Rs 1119 crore, Net Profit at Rs 105.6 crore
Strides Pharma Science Ltd reported a strong performance for the quarter ended June 30, 2025, with revenue from operations rising 6.2% YoY to ₹1119.7 crore. The company’s operational profit after tax ...
Strides Pharma receives USFDA approval for Celecoxib Capsules
Strides Pharma Science Limited announced that its stepdown wholly owned subsidiary, Strides Pharma Global Pte. Limited, based in Singapore, has received approval from the United States Food & Drug Adm...
Strides Pharma incorporates new subsidiary ‘Pivot Path’ to boost life sciences and digital innovation
Strides Pharma Science Limited has announced the incorporation of a new step-down wholly owned subsidiary named Pivot Path Private Limited through its subsidiary Arco Lab Private Limited. The new enti...
Strides Pharma shares surge 5% as revenue jumps 15% YoY in Q3 FY25
Strides Pharma Science Limited’s shares rose 5% following the release of its Q3 FY25 financial results, showcasing robust year-on-year (YoY) growth and a strong profit recovery. As of 1:43 PM, the sha...
Strides Pharma Q3 FY25 Results: Revenue up 15% YoY to Rs 1,154 crore, Net Profit up 60% YoY
Strides Pharma Science Limited reported its Q3 FY25 financial performance with strong year-on-year (YoY) revenue growth and a significant improvement in net profit. The company’s revenue from operatio...
Strides Pharma receives USFDA approval for acetaminophen and ibuprofen tablets, expanding OTC portfolio
Strides Pharma Science Limited has announced a significant milestone with USFDA approval for acetaminophen and ibuprofen tablets, 125 mg/250 mg. This development is set to enhance the company’s over-t...
Strides Pharma Science Q2 FY25 Results: Net profit surges to ₹93.7 crore, US revenues hit historic high
Bangalore, India, October 24, 2024 – Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) has announced impressive financial results for the second quarter of FY25, showcasing significant year-on-year ...
OneSource raises Rs 801 crore from investors, boosts growth for Strides shareholders
Strides Pharma Science’s associate company, OneSource Specialty Pharma, has successfully raised INR 801 crore (approximately USD 95 million) from marquee investors at a pre-money valuation of USD 1.65...
Strides Pharma shares surge 3% on USFDA nod for Fluoxetine Tabs 60 mg
Shares of Strides Pharma Science Ltd. jumped 3% after the company announced that its subsidiary, Strides Pharma Global Pte. Limited, Singapore, received USFDA approval for Fluoxetine Tablets 60 mg. Wi...
Strides Pharma gets USFDA approval for Fluoxetine Tabs 60 mg
Strides Pharma Science Limited (Strides) has recently informed exchanges that its step-down fully owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has obtained FDA approval for Fluoxet...
Strides Pharma secures approval for OneSource, India’s first specialty pharma CDMO
Strides Pharma Science Limited (Strides) informed exchanges that it received overwhelming approval from its equity shareholders and secured creditors, as well as those of OneSource Specialty Pharma Li...
Strides Pharma Science share jumps 2.62% after getting USFDA approval for Theophylline Extended-Release tablets
Strides Pharma Science shares jumped more than 2% after getting USFDA approval for Theophylline Extended-Release tablets. In the exchange filing the company said, “Strides Pharma Science Limited (Stri...
Strides Pharma Science gets USFDA nod for Theophylline Extended-Release tablets
Strides Pharma Science Limited has recently informed exchanges that its step-down entirely owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for the generic versio...
Strides Pharma Science shares at 9-year high after US subsidiary closure
Strides Pharma Science Ltd.'s shares surged to a nearly nine-year high on Friday, following the company's decision to cease operations of its US subsidiary, Altima Innovations Inc.